| NCT ID | NCT06665373 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Malignant Glioma |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15 participants in total. It began in 2024-10-01 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a pilot study assessing the effects of combining a modified Atkins diet with a physical fitness regimen in patients with malignant glioma. A sample size of 15 participants will be enrolled in a 15-week program consisting of two weekly supervised exercise sessions combined with an individualized home exercise program and a modified Atkins diet.
Eligibility Criteria
Inclusion Criteria: * Tissue confirmed diagnosis of high-grade glioma (World Health Organization grade III or IV) * Karnofsky Performance Status (KPS) ≥ 70% * Willing to follow the study intervention and follow-up * Able to give full informed consent Exclusion Criteria: * Currently undergoing initial concurrent radiation/chemotherapy * Severe medical co-morbidities * Any medical condition which prohibits moderate to vigorous physical activity (60-85% HRmax) * Any medical condition which prohibits a restrictive diet * Neurological deficit preventing participation in moderate to vigorous physical activity * Severe psychiatric illness
Contact & Investigator
Lee Tessler, MD
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT06665373 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Malignant Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06665373 currently recruiting?
Yes, NCT06665373 is actively recruiting participants. Contact the research team at Cathryn.lapierre@nyulangone.org for enrollment information.
Where is the NCT06665373 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06665373 clinical trial?
NCT06665373 is sponsored by NYU Langone Health. The principal investigator is Lee Tessler, MD at NYU Langone Health. The trial plans to enroll 15 participants.